ArticleNature communications2020

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.

Rong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.